Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic designed to treat diabetic macular edema (DME) and related eye conditions. …
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be presented during a late-breaking clinical trials session at the American College of …
Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 Read More
AUSTIN, TX & PHILADELPHIA, PA — Faeth Therapeutics and The GOG Foundation, Inc. have announced a significant milestone in the fight against endometrial cancer. The first patient has been dosed in …
Faeth Therapeutics and GOG Foundation Launch Pioneering Phase 2 Trial for Advanced Endometrial Cancer Read More
PHILADELPHIA, PA — iECURE, Inc. has announced that early data from its Phase 1/2 OTC-HOPE clinical trial, evaluating the gene-editing candidate ECUR-506 for neonatal onset ornithine transcarbamylase (OTC) deficiency, will be …
iECURE to Present Promising Initial Data from Gene Editing Trial for Neonatal OTC Deficiency Read More
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader, NKT3964, by completing the dosing of the first patient cohort in a …
NiKang Advances CDK2 Degrader with Key Milestone in Cancer Treatment Trial Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal antibodies (DMAbs) for COVID-19. Impressively, 100% of participants who reached …
INOVIO Reports Groundbreaking Results in COVID-19 Antibody Trial Read More
SPRING HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human clinical trial. This milestone marks the company’s transition to …
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study Read More
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for …
Endo, Inc. Shares Positive Data on XIAFLEX Treatment for Peyronie’s Disease Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active …
Johnson & Johnson Reports Positive Study Results for Ulcerative Colitis Treatment Read More
EXTON, PA — Lungpacer Medical has announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for the STARI (STimulation to Activate RespIration) clinical trial. …
Lungpacer Medical Secures FDA Approval for AHRF Trial Read More